Poor angioplasty sales drag down Pfizer's results
This article was originally published in Clinica
Declining sales of Pfizer's angioplasty and urology products led to flat growth in the company's medical technology sector, where sales rose only 1% to $1.5 billion in 1997. The company attributes this to pricing pressures and new product competition.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.